MIAMI--(BUSINESS WIRE)--Dec. 19, 2005--IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for clozapine tablets USP, 200 mg. This product will be sold through IVAX’ wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Clozapine is the generic equivalent of Clozaril(R) which is marketed by Novartis and used in the treatment of schizophrenia. The drug is currently available in 100, 50, 25 and 12.5 mg tablet dosage strengths. The 200 mg tablet is a new dosage strength developed by IVAX to create additional dosing options. According to IMS data, annual U.S. sales for Clozaril and its generic equivalent clozapine were $135.5 million for the twelve months ended September 30, 2005. IVAX currently has a market share of 53% of the total (Clozaril and its generic equivalent combined) market’s extended units.
